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Five neutralisation epitopes have been defined for the O1 Kaufbeuren strain of foot-and-mouth disease virus (FMDV) by
neutralising murine monoclonal antibodies (Mabs). A mutant virus which is resistant to all these Mabs also resists
neutralisation by bovine polyclonal sera, and this characteristic was exploited in the current study to investigate the biological
relevance of neutralisation sites in FMDV virulence and vaccine protection. The five site neutralisation-resistant mutant was
shown to be as pathogenic as wild-type virus in the guinea pig model of FMD. Guinea pigs were protected in cross-challenge
studies from virulent wild-type and mutant viruses using either wild-type or mutant 146S antigen as inactivated whole virus
vaccine. Furthermore, hyperimmune sera raised to either wild-type or mutant antigen offered passive protection against
wild-type challenge, in spite of the serum raised against the mutant antigen having minimal neutralising activity in vitro. These
results imply that virus neutralisation, at least as defined by the in vitro assay, may not play an essential role in the
mechanism of immunity induced by whole inactivated FMDV vaccines. © 1998 Academic Press
INTRODUCTION
The existing knowledge of the capsid structure of
foot-and-mouth disease virus (FMDV) (Acharya et al.,
1989; Lea et al., 1995; Hewat et al., 1997), and other
picornaviruses (Hogle et al., 1985), is very detailed and
many epitopes (Wimmer et al., 1984; Mateu, 1995) have
been identified on the surface of the virion by neutralis-
ing murine monoclonal antibodies (Mabs). The amino
acid residues which constitute these neutralisation
epitopes of the FMDV capsid have been defined by
sequencing resistant viruses and then grouped into in-
dependent antigenic sites. This has been accomplished
for several FMDV serotypes (Pfaff et al., 1988; Thomas et
al., 1988; McCahon et al., 1989; Saiz et al., 1991) and point
mutations are usually sufficient to confer resistance to
neutralisation. However, no information is available on
the biological relevance of these sites for virulence or
their contribution to vaccine protection.
The FMDV O1 Kaufbeuren strain may be unique in that
five neutralisation sites have been identified by murine
Mabs (McCahon et al., 1989; Kitson et al., 1990; Crowther
et al., 1993). Indeed a mutant O1 Kaufbeuren virus which
escapes neutralisation from five Mabs identifying
epitopes within each of the antigenic sites has been
reported to be resistant to polyclonal serum from bovines
vaccinated with homologous virus (Crowther et al., 1993).
No studies have investigated the potential pathogenicity
of neutralisation-resistant FMDV as a means of defining
whether the wild-type epitopes are essential for full vir-
ulence and therefore whether resistant viruses could
play a role in FMD epidemiology. Knowledge of the
virulence of neutralisation-resistant mutants, or mutants
with distinct antigenic profiles from the wild type, has
been ascertained for a range of viruses (Kumel et al.,
1985; Gould et al., 1989; Johnson et al., 1990; Kovamees
et al., 1990; Cecilia and Gould, 1991; Holzmann et al.,
1997; Ryman et al., 1997), including picornaviruses (Dia-
mond et al., 1985; Roos et al., 1989; Zurbriggen and
Fujinami, 1989; van Houten et al., 1991), but not for FMDV.
The importance of neutralisation of FMDV extends
beyond the fundamental knowledge of the localisation of
epitopes to the more applied aspects of vaccine protec-
tion (Pay and Hingley, 1986), antigenic relatedness, and
vaccine selection (Rweyemamu, 1984; Kitching et al.,
1989). Vaccination of susceptible cloven-hooved live-
stock with inactivated whole virus vaccines is one of
several measures available to animal health authorities
to control FMDV. Epidemics of FMD are a constant threat
to domestic livestock production systems throughout the
world. The recent outbreak of FMDV serotype O in Tai-
wan (Anonymous, 1997; Dunn and Donaldson, 1997) is a
reminder of the devastating nature of the disease and its
impact on the economy of a whole region. The search
continues for improved vaccine strategies (Brown, 1992)
but in common with many efficacious commercial vac-
cines, the nature of the protective immune response
induced by the whole inactivated FMDV vaccines has not
yet been defined. Parameters such as serum neutralisa-
tion titre (Pay and Hingley, 1992), antibody affinity
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(Mulcahy et al., 1992; Steward et al., 1991), and even
antibody titre on ELISA (Hamblin et al., 1987; Van
Maanen and Terpstra, 1989; Periolo et al., 1993) have
been established and successfully applied as in vitro
correlates of protective immunity. However, the relative
importance of neutralisation per se (McCullough et al.,
1987) as one of several potential mechanisms of inacti-
vated vaccine protection has not been established. Other
likely components of this protective immunity do exist but
these are difficult to assay in vitro (McCullough et al.,
1992). Consequently, consideration should also be given
to nonneutralising antibodies in determining FMD vac-
cine selection as use of the ELISA measuring antibodies
to the whole virus (Kitching et al., 1988) to determine
antigenic relatedness could therefore be more pertinent
than an assay based on neutralisation (Rweyemamu,
1984).
Our studies were intended to further the understand-
ing of the biological significance of neutralisation
epitopes as viral factors in virulence using the guinea pig
model of FMD (Knudsen et al., 1979, 1982, 1983; Di
Girolamo et al., 1985; Bartels et al., 1994). The contribu-
tion of these neutralisation epitopes to whole inactivated
vaccine protection in guinea pigs was explored by con-
ducting cross-challenge experiments. We worked on the
hypothesis that a conventional inactivated FMDV vaccine
based on the O1 Kaufbeuren five site neutralisation es-
cape mutant virus would induce only low titres of serum
neutralising antibodies to wild-type virus and therefore
would not protect against virulent wild-type challenge.
RESULTS
Passage of wild-type and mutant viruses
in guinea pigs
Virus stocks and all isolates of virus made from vesic-
ular lesions were checked for reactivity with Mabs by an
indirect ELISA. As anticipated, none of the five Mabs
bound to the mutant stock virus in spite of OD values
being in excess of 1.0 for a specific murine polyclonal
serum. All Mabs reacted with the stock wild-type virus.
The distinct positive (wild type) and negative (mutant)
Mab profile was repeated for all guinea pig isolates of
the respective viruses up to the sixth passage. However,
the mutant virus isolated from one animal on the first
passage had reverted at the fifth site, defined by positive
reactivity with Mab OC3. Profiling of the virus isolated
from footpad lesions on the subsequent passage in two
guinea pigs demonstrated the original negative reactivity
at all five epitopes for the isolate from one of the animals.
This latter virus was passaged two more times and
resulted in the isolation of viruses with the five site
mutant profile at each attempt.
The severity of the primary footpad lesions caused by
both viruses increased on passage. From the fourth
passage, both the wild-type and the mutant viruses
caused generalised disease with secondary vesicles
being more severe on the uninoculated hind pad than on
the fore feet. There was no detectable difference in the
severity of the lesions induced by the wild-type and
mutant viruses. No lesions were detected on the tongue,
even on the sixth passage.
Characterisation of serum from wild-type and
mutant vaccinees
The 146S wild-type and mutant antigen stocks were
first shown to be immunogenic in guinea pigs by testing
sera at a dilution of 1:2500 using an indirect ELISA. The
level of serum antibodies detected in animals at 28 days
postvaccination was shown to be similar (Fig. 1). The
median values for the optical densities of wild-type and
mutant vaccinees (n 5 5) were 0.56 and 0.61, respec-
tively. The difference in these values was not statistically
significant at P ,0.05 when analysed using the Mann–
Whitney U test. Negative guinea pig control sera had
optical densities of less than 0.05 even at 200-fold dilu-
tions.
Hyperimmune serum taken from these animals after
boosting was titrated for neutralising antibodies against
the wild-type and mutant stock viruses (Fig. 2). Guinea
pigs vaccinated with the mutant antigen were shown to
have very low levels of neutralising antibodies when
their sera were titrated against wild-type virus relative to
guinea pigs vaccinated with the wild-type antigen. Fur-
thermore, sera from wild-type vaccinees had poor neu-
tralising activity against mutant virus and mutant vacci-
nee sera had higher neutralising titres against the ho-
mologous virus compared to wild-type virus. The pooled
hyperimmune sera raised to the respective antigens
have similar antibody titres on indirect ELISA (Fig. 3a).
The sera were also titrated against increasing infectivi-
ties of the wild-type virus (Fig. 3b), and the difference in
neutralisation titres ranged from 0.75 to 1.1 log.
FIG. 1. Detection of antibodies to whole inactivated FMDV in guinea
pig sera by indirect ELISA at 28 days after vaccination with either
wild-type or mutant antigen.
52 DUNN ET AL.
The five wild-type hyperimmune sera were demon-
strated to have antibodies which bound to the same sites
on the native capsid as the five murine Mabs by using
the competition ELISA assay (Figs. 4a–4e). Conversely,
the inhibitory effect on Mab binding of sera from animals
hyperimmunised with the mutant antigen was low or
negligible compared to the five equivalent wild-type sera.
Cross-challenge vaccine studies
The VacMan programme calculated the MID50 and
MCD99.9 for the challenge virus stocks as shown in Table
1. The inoculation of guinea pigs vaccinated with either
wild-type or mutant antigen using 1 MCD99.9 of either
wild-type or mutant challenge virus did not result in even
primary lesions in any of the vaccinees. Secondary le-
sions were apparent in all but two of the control animals
inoculated with mutant virus. A rise in serum antibody
level detected by the indirect ELISA 1 week after chal-
lenge in all groups of animals indicates that this immu-
nity was not sterile (Fig. 5). Therefore using the appear-
ance of primary lesions as the criterion of nonprotection,
the wild-type antigen protected guinea pigs against wild-
type or mutant virus challenge and likewise for the mu-
tant antigen.
Guinea pigs were protected against generalised ve-
sicular disease when challenged with the sixth-passage
wild-type virus after passive immunisation with the wild-
type pooled hyperimmune serum. The animals passively
immunised with the mutant pooled hyperimmune serum
were also protected against this wild-type challenge
(Table 2). All control animals developed generalised dis-
ease by 3 days postchallenge, as did guinea pigs inoc-
ulated with the smallest infecting dose in the titration, a
103 dilution of stock virus.
FIG. 2. Fifty percent neutralising antibody titres to wild-type and mutant virus of individual hyperimmune guinea pig sera raised to either wild-type
(a) or mutant antigen (b).
FIG. 3. The pooled hyperimmune sera raised to the respective wild-type and mutant antigens were analysed for antibodies to whole FMDV particles
by indirect ELISA (a) and neutralising antibodies to a range of wild-type challenge virus doses (b) prior to the passive immunisation experiment.
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DISCUSSION
A series of point mutations occur in the FMDV O1
Kaufbeuren capsid to enable the virus to escape neutral-
isation when a selection of five Mabs is incubated with
the virus in cell culture (Crowther et al., 1993). We have
now demonstrated that the five site mutant virus can
cause generalised vesicular lesions in guinea pigs. Fur-
thermore, cross-challenge studies demonstrate that an-
tibodies to these five wild-type epitopes are not neces-
sary for the protection induced by inactivated whole virus
vaccines. We commenced this study with the hypothesis
that animals inoculated with the mutant vaccine would
not resist wild-type challenge due to the failure of vac-
cinees to recognise several neutralisation epitopes and
so to develop a cross-reactive virus neutralisation titre.
Conversely, if neutralising antibodies were an essential
component of the protective immune response, wild-type
vaccinees should not have been able to resist virulent
mutant challenge. The results of the current studies did
not support the original hypothesis.
The three-dimensional structure of the quadruple Mab
escape mutant G67 has been compared to the wild-type
virus and only differs from the mutant by retaining the
OC3 site (Lea et al., 1995). The alteration in the virus
capsid structure which occurs to permit resistance to
neutralisation is minor; the point mutations only affect
the side chains of the capsid. Although it might have
been assumed from these structural data that the mutant
virus would still be infectious, the ability of a virus with
the mutant phenotype to cause vesicular disease is a
significant finding. Single Mab escape mutants of Thei-
ler’s murine encephalitis have a similar virulence to wild-
type virus during the acute stages of infection but a much
reduced virulence in the chronic stages of disease (Roos
et al., 1989; Zurbriggen and Fujinami, 1989). The anti-
genic variation in the five epitopes of interest was mini-
mal on passage in guinea pigs and the reversion which
occurred at the fifth site was not stable on subsequent
passage. These findings, although drawn from a limited
set of data, support the use of the guinea pigs for po-
tency testing of FMD vaccines because the antigenic
profile of this virus strain did not change during adapta-
tion to the model system. As only two of four guinea pigs
inoculated with this challenge stock of five site mutant
virus developed secondary vesicular lesions, there is the
possibility that virulence is impaired by the mutations.
We have no data which allow us to compare viral load in
wild-type and mutant inoculated animals but the severity
of the primary and secondary lesions induced by the two
viruses was similar and generalised disease was ob-
served after the fourth passage of each virus. Recently
we have inoculated the challenge stock of the five site
mutant into cattle and confirmed its pathogenicity in this
natural host by observing generalised vesicular lesions
(C. Dunn and E. Green, unpublished results).
The indirect ELISA data indicates that the respective
146S antigen of wild-type and mutant viruses is equally
immunogenic in guinea pigs. Before commencing the
challenge of actively vaccinated animals, it was impor-
tant to establish the relative immunogenicity. Disparate
serum antibody levels might explain the difference in
serum neutralisation titres elicited in vaccinees and any
resulting vaccine protection (Hamblin et al., 1987). How-
ever, guinea pigs inoculated with the mutant vaccine
were protected from wild-type challenge in spite of the
inability of mutant antigen to stimulate high levels of
serum neutralising antibodies. Likewise, passive protec-
tion against the more virulent wild-type challenge was
accomplished using the pooled hyperimmune serum
raised to the mutant antigen. The latter serum had a very
low titre of neutralising antibodies compared to the cor-
responding wild-type serum but a similar titre of antibod-
ies to whole virus when analysed by indirect ELISA. The
passive prophylaxis experiment was partly undertaken to
see if serial dilutions of serum could reveal a quantitative
difference in the protective capacity of the respective
hyperimmune serum pools. No difference was revealed
although the dilutions were not high enough to demon-
strate the limit of protection of either serum.
Vaccine protection can therefore be generated to a
virulent wild-type virus using a mutant antigen lacking
five neutralising epitopes, which suggests that the abso-
lute serum neutralisation titre (Pay and Hingley, 1992) is
not universally applicable as a correlate of protection
TABLE 1
The Titration of Challenge Stocks of Virus in Guinea Pigs by the Intradermal Route was Analysed by the VacMan Program
Virus Passage
No. guinea pigs infected/No. inoculated (log dilution of inoculum)
MID-50%a MCD-99.9%0 1 2 3 4 5 6
Wild type 4 — 2/2 2/2 2/3 2/4 0/4 0/2 2547 107
Mutant 4 2/2 3/3 4/4 2/3 1/3 — — 1892 72
Wild type 6 — — 2/2 2/3 0/3 0/2 — 1138 32
a Infectivity is expressed as the number of MID50 and MCD99.9 per 30 ml (the unit volume of inoculum) of undiluted inoculum. Inoculating 1 MCD99.9
has a 0.1% probability of not infecting an animal.
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(Doel et al., 1994), especially for novel immunogens (Di-
Marchi et al., 1986; Doel et al., 1990; Mulcahy et al., 1991).
This provokes reflection on nonneutralising mechanisms
of vaccine immunity (McCullough et al., 1988, 1992).
Exploiting the mouse model of passive protection using
FMDV O1 Suisse, McCullough et al. (1986) demonstrated
that certain of the neutralising Mabs used in this study
will protect in vivo at antibody:virion molar ratios which
are much lower than those required for in vitro neutral-
isation. Opsonisation of the viral particle at low antibody
titre will still promote phagocytosis and the 50% protec-
tive dose of a given Mab for mice is much greater than
the corresponding neutralisation titre. The antibodies to
the whole virus particle detected by indirect ELISA in the
current study could mediate protection by opsonisation
and of course such antibodies are not required to have
neutralising activity.
The efficacy of nonneutralising Mabs in protecting
from infection and disease has been demonstrated in
a variety of murine models of viral pathogenesis (Bal-
achandran et al., 1982; Schmaljohn et al., 1982; Lefran-
cois, 1984; Taylor et al., 1984; Boere et al., 1985; Gould
TABLE 2
Guinea Pigs Were Challenged Using 3.2 MCD99.9 of 6th Passage
Wild-type Virus 24 h after Passive Prophylaxis Using either Wild-type
or Mutant Pooled Hyperimmune Serum
Antigen used to raise
hyperimmune serum
No. guinea pigs with generalised
lesions/No. inoculated
(volume of serum inoculated (ml))a
2 1 0.5 0.25 0
Wild type 0/3 0/3 0/3 0/3 2/2
Mutant 0/3 0/3 0/3 0/3 2/2
a The volume of sera was made up to 2 ml with PBS prior to
subcutaneous injection.
FIG. 5. Detection of antibodies by indirect ELISA in guinea pig sera diluted 1:2000 prior to and 7 days after challenge. Animals challenged by wild-type virus and
vaccinated with wild-type antigen (a) or mutant antigen (b); animals challenged by mutant virus and vaccinated with wild-type antigen (c) or mutant antigen (d).
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et al., 1986; Virgin et al., 1988). However these non-
neutralising antibodies might not be induced in suffi-
cient amounts by a particular field vaccine in order to
allow protection. Also, these studies give no indication
as to the relative extent that the protective efficacy of a
given field vaccine depends on neutralising and nonneu-
tralising antibodies. Once the contribution of nonneutral-
ising antibody-mediated mechanisms of FMD vaccine
immunity become appreciated and then quantified, im-
proved correlates could be devised to permit the re-
placement of in vivo potency testing. The practical rele-
vance of such antibodies also extends to FMD vaccine
selection as the tests to determine antigenic relatedness
of strains of FMDV (Kitching et al., 1989) can be based on
a comparison of the titre of the outbreak strain relative to
that of a reference strain by either a neutralisation test
(Rweyemamu, 1984) or an ELISA assay using whole virus
particles (Kitching et al., 1988). Obviously the neutralisa-
tion tests could underestimate the protective potential of
a given vaccine should nonneutralising antibodies play a
significant role. Similarly, the determination of antigenic
relatedness between FMDV strains by Mab profile for the
purpose of vaccine selection (Samuel et al., 1991; David-
son et al., 1995) should include a range of protective
nonneutralising Mabs as well as neutralising Mabs.
The interpretation of any vaccine challenge experiment
should consider a range of variables, including the chal-
lenge dose, route of inoculation, antigen dose, and the
criteria used to define protection (Pay and Hingley, 1986).
The virulence of challenge virus is less well recognised as
a quantifiable parameter. With respect to this point, it
should be noted that this passive humoral immunisation
protected all animals from generalised vesicular lesions
and only few from primary lesions, thus contrasting with the
active immunisation experiment where all animals were
protected from primary lesions. This difference may be due
to a more highly passaged challenge virus being used at a
higher dose in the passive immunisation experiment. Past
experience of our vaccine potency testing in guinea pigs
has shown that it is typical for FMDV to reproducibly gen-
eralise after five passages and the O1 Kaufbeuren strain
does not usually generalise to the tongue (L.A.P., unpub-
lished data).
The competition ELISA data gave encouraging evi-
dence for the relevance of murine Mabs to the guinea pig
humoral immune response since serum from animals
vaccinated with wild-type 146S antigen blocked Mabs
from binding to the respective neutralisation epitopes.
Serum from mutant vaccinees had no or low inhibition of
Mab binding, so the guinea pigs were obviously not
recognising any new epitopes created by the point mu-
tations which permitted escape from Mab neutralisation.
Conversely, Borrego et al., (1995) found that the immu-
nogenicity of site A of FMDV serotype C was retained by
a variant virus which escapes Mab neutralisation. The
information from the competition ELISA therefore corre-
lates well with the serum neutralisation titres because
the failure of serum to block the binding of these partic-
ular Mabs indicates diminished neutralisation activity.
Serum from guinea pigs vaccinated with the wild-type
antigen had a small, but detectable, neutralising titre to
the mutant virus and mutant vaccinee serum also weakly
neutralised wild-type virus. This indicates that the mutant
virus has at least one more neutralisation epitope. As
mutant vaccinee sera more effectively neutralised mu-
tant virus than wild-type virus, any remaining epitopes on
the mutant antigen may become more immunogenic.
This situation parallels that of poliovirus type 3; when the
virus is treated with trypsin, antigenic site 1 on the BC
loop is lost (Icenogle et al., 1986; Roivainen and Hovi,
1987) and the virus resists neutralisation by polyclonal
sera (Roivainen et al., 1993). However, the neutralising
activity of Mabs which recognise alternative sites on the
capsid increases (Roivainen et al., 1990) and individuals
vaccinated with the trypsin-treated antigen respond to
the remaining neutralisation sites better than wild-type
vaccinees (Piirainen et al., 1997).
The genuine mechanism of protection mediated by inac-
tivated whole FMDV vaccines remains to be elucidated.
Indeed, the mechanism which protects against generalisa-
tion of disease may not be the same as that which permits
resistance to mucosal challenge. Attempts to correlate se-
rum neutralisation titre to the potency of these vaccines
have been driven by the belief that neutralisation is the
predominant component in the mechanism of protection.
This study used a model system which suggests that an
elevated serum neutralising antibody titre is a dispensible
element of the protective humoral immune response in-
duced by the inactivated FMD vaccines. This is another
step towards recognising the importance of other antibody-
mediated protection mechanisms (McCullough et al., 1992)
and, eventually, the development of better correlates of
vaccine potency to obviate in vivo testing. Ultimately it will
be important to demonstrate that the vaccine potency of a
biologically modified antigen does extend to natural host
species, to other FMDV serotypes, and to mucosal chal-
lenge situations.
METHODS
Preparation of virus stocks, titration of infectivity, and
neutralising Mabs
The FMD O1 Kaufbeuren/FRG/66 wild-type virus was
obtained from the OIE/FAO World Reference Laboratory
for FMD at Pirbright and the five site escape mutant
virus, referred to below as the mutant virus, was derived
by sequential incubation of wild-type virus with the Mabs
as previously described by Crowther et al. (1993). The
Mabs B2, C9, C8, 14EH9, and OC3 identify epitopes
within the FMDV O1 Kaufeuren neutralisation sites 1 to 5,
respectively. The amino acid residues implicated in the
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binding of these Mabs have been detailed elsewhere
(Kitson et al., 1990; Crowther et al., 1993).
Stocks of wild-type and mutant viruses were prepared
on the porcine kidney cell line IB-RS-2, which was main-
tained as a monolayer at 37°C in an humidified atmo-
sphere of 5% CO2 in Dulbecco’s medium, supplemented
with 5% foetal calf serum (FCS), 2 mM glutamine, and 100
U/ml penicillin with 10 mg/ml streptomycin. When the
monolayer showed full cytopathic effect, culture super-
natant was harvested and clarified, diluted 1:2 with glyc-
erol, and stored at 220°C. The virus stocks were titrated
for infectivity in 96-well plates using 10-fold serial dilu-
tions in replicates of 8 and cytopathic effect (c.p.e.) was
observed at 24 h. Viral infectivity was expressed as the
50% tissue culture infectivity dose (TCID50) using the
Karber formula (Karber, 1931).
Neutralisation assays were performed using wild-type
and mutant viruses which had been adapted following 12
passages on the baby hamster kidney (BHK) cell line,
clone 21. Virus stocks were produced and monolayers of
cells were maintained in Dulbecco’s medium supple-
mented as described above. Sera from individual guinea
pigs, five vaccinated and boosted with wild-type virus
and five with mutant virus, were diluted by serial three-
fold dilutions in medium and dispensed in microtitre
plates at 50 ml per well in replicates of four. Both viruses
were titrated for infectivity on BHK cells and stocks
diluted in medium to give 100 TCID50 per 50 ml, which
was then added to the wells, making the first serum
dilution 1:20. Following a 30-min incubation at 37°C, BHK
cells in medium with 5% FCS were added.
Passage of mutant and wild-type viruses
in guinea pigs
All animal experimentation was performed in accor-
dance with the appropriate UK legislation directed by the
Home Office. Adult Dunkin–Hartley guinea pigs (David
Hall Ltd., UK) weighing more than 500 g were maintained
as previously described (Pullen, 1980) and inoculations
of virus were by the intradermal route using one hind
footpad. Passage of viruses commenced with the origi-
nal stocks using an inoculum of 106 TCID50 in 30 ml.
When a primary lesion appeared, vesicular fluid (VF) was
obtained by flushing with 0.5 ml sterile phosphate-buff-
ered saline (PBS). Virus was isolated by incubation of VF
for 30 min on monolayers of IB-RS-2 cells in 12-well
plates (Corning, UK) which had been washed with PBS to
remove serum. The inoculum was washed off by rinsing
three times with PBS and replaced with medium. When
an extensive c.p.e. was observed, the culture superna-
tant was stored at 220°C, titrated for infectivity, and
inoculated into two or three naive guinea pigs. This
routine was repeated at each passage after profiling the
virus using Mabs.
Profiling of virus stocks and isolates
by indirect ELISA
The Mabs B2, C9, C8, 14EH9, and OC3 (McCahon et
al., 1989; Crowther et al., 1993) were obtained as culture
supernatants and used at saturating dilutions in an indi-
rect ELISA (Samuel et al., 1991). Briefly, rabbit hyperim-
mune serum raised to FMDV O1 BFS was used as trap-
per, diluted in carbonate/bicarbonate buffer, pH 9.6
(Sigma, UK), before being dispensed in wells of microti-
tre plates (Maxisorb; Nunc, UK) and incubated at 4°C
overnight. Volumes of 50 ml were used throughout and
incubations were followed by flooding and emptying the
plate three times with PBS. Viral antigen was added to
wells as culture supernatants diluted with an equal vol-
ume of a blocking buffer consisting of 5% skimmed milk
powder in PBS (Marvel; Cadbury, UK) and 0.1% Tween 20
(Sigma, UK). This was followed by an incubation with the
Mabs diluted in the same buffer. All tests included a
polyclonal murine serum raised to the O1 BFS strain as a
control to ensure that sufficient virus antigen was
present. Bound Mab or polyclonal antibody was detected
using a rabbit anti-mouse horseradish peroxidase con-
jugate (HPRO; Dako, UK) with hydrogen peroxide as
substrate and o-phenylethylenediamine (Sigma, UK) as
chromogen. The reaction was stopped with 1.25 M sul-
phuric acid and optical density read at 492 nm. An optical
density in excess of three times the background values
was considered positive.
Immunisation of guinea pigs and preparation
of hyperimmune sera
Guinea pigs were immunised with FMD whole inacti-
vated virus particles prepared from cultures infected with
either wild-type or mutant viruses. The IB-RS-2 cells were
infected in roller bottles and when c.p.e. was complete,
the culture supernatant was harvested, clarified by cen-
trifugation, and treated with 1 mM binary ethylenimine at
37°C for 24 h to inactivate the virus (Bahnemann, 1975,
1990). The 146S antigen represents whole virus particles
and was concentrated from culture supernatant by poly-
ethylene glycol precipitation before sucrose density gra-
dient purification (Minor, 1986). Fractions of 1 ml were
collected from the gradients and the optical density at
259 nm was measured to quantify the antigen. The peak
fractions were stored at 270°C.
An emulsion of 5 mg of 146S antigen was made on
adding Freund’s complete adjuvant (Sigma, UK) at a 1:1
ratio with either wild-type or mutant antigen diluted in a
Tris–salt buffer (Minor, 1986). Two groups of five guinea
pigs were injected by the subcutaneous route with one of
each emulsion and bled for serum at 28 days postvac-
cination when they were given a booster of 5 mg of
antigen in Freund’s incomplete adjuvant (Sigma, UK).
These animals were killed 10 days later and exsangui-
nated. The serum fraction was prepared and stored for
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each individual animal and a pool of hyperimmune se-
rum raised to each virus antigen was made by mixing
approximately equal volumes of the individual sera. De-
bris was removed from the hyperimmune sera after cen-
trifugation by using 0.45-mm-pore size disposable filters
(Sigma, UK). Sera were decomplemented by heating at
56°C for 30 min.
Detection of FMDV antibodies in guinea pig serum
by indirect ELISA
A modification of the protocol described by Abu Elzein
and Crowther (1978) was used. All incubations were for
1 h at 37°C on an orbital shaker and were followed by
washing the plate three times with PBS. Briefly, the 96-
well microtitre plates were coated with anti-FMDV O1
BFS rabbit hyperimmune sera as described above. The
146S wild-type antigen was diluted to 1 mg/ml in blocking
buffer and then the guinea pig test sera were added at
appropriate dilutions. The detection system was as de-
scribed above but used a rabbit anti-guinea pig HPRO
conjugate (Dako, UK). Three negative control guinea pig
sera were used to validate the test and at least two
negative sera were included in test runs. The Mann–
Whitney U test was used to determine the significance of
the difference in the median optical density values for the
wild-type and mutant vaccinees at a serum dilution of
1:2500.
Competition ELISA
The indirect ELISA protocol for the assay of antibodies
in guinea pig serum was followed but the Mabs were
incubated for 1 h at 37°C after the guinea pig serum was
washed off and then detected using a rabbit anti-mouse
HPRO conjugate. Normal decomplemented bovine se-
rum was added to the blocker at 1% w/v. The percentage
inhibition for each guinea pig serum was calculated
(Thevasagayam et al., 1995) using the mean of two neg-
ative guinea pig sera on each test plate to determine
zero percentage inhibition. The background optical den-
sity for individual plates was subtracted from the reading
of each test well and determined using wells where Mab
was omitted.
In vivo titration of wild-type and mutant challenge
viruses
Isolates of wild-type and mutant virus were made from
primary vesicular lesions appearing on the fourth passage
of virus in guinea pigs. A stock of each virus was made and
serial 10-fold dilutions starting from 1021 were inoculated
into footpads using two to four animals per dilution. Ani-
mals were observed for the appearance of primary and
secondary vesicles up to day 7 postinoculation. A second
stock of wild-type virus was isolated from a secondary
lesion resulting from the sixth passage of virus in guinea
pigs and titrated as described above. The mean infectious
dose-50% (MID50) and minimal challenge dose-99.9%
(MID99.9) were calculated from the raw titration data using
the ‘‘VacMan’’ program described by Spouge (1992). The
Mab profiles of the challenge viruses and their isolates
obtained from the titration experiments were verified prior
to commencing the prophylaxis studies.
Virulent challenge of actively and passively
immunised guinea pigs
Ten guinea pigs were vaccinated with 5 mg of 146S
wild-type antigen in Freund’s complete adjuvant and,
likewise, 10 animals with 5 mg of the mutant antigen.
These were the same stocks of antigen used to obtain
the hyperimmune serum described above. Eight guinea
pigs were mock vaccinated and animals were bled and
challenged at 32 days postvaccination. Half of the control
animals and half the animals of each vaccine group were
challenged intradermally with 1 MCD99.9 of fourth-pas-
sage wild-type virus stock and the other half of each
group were challenged with the same dose of mutant
virus. The operator (L.A.P.) was blind to the identity of the
challenge viruses.
The pools of hyperimmune serum raised against 146S
wild-type and mutant antigen were used to passively
immunise guinea pigs 24 h prior to challenge with a
10-fold dilution of the wild-type stock virus isolated from
the sixth passage. This represented a dose of 3.2
MCD99.9. Three serial 2-fold dilutions of each hyperim-
mune serum were made in PBS. Individual guinea pigs,
in groups of three, were each injected subcutaneously
with 2 ml of either pure or diluted serum. Control animals
were injected with PBS only.
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